News

At NGM, we pride ourselves on conducting world-class science and sharing our research efforts with the broader scientific and medical communities.

Select section

Jun 08, 2016

NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH

Read more View PDF